DNTH vs IR · rev $6.2M vs P/E 49, rev $7.24B
Dianthus Therapeutics Inc. (DNTH) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
DNTH currently screens at market cap $4.40B. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the DNTH and IR stock pages for the full models.
Not investment advice.